atenolol has been researched along with Diabetes Mellitus in 33 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our current aims were to investigate whether 1) baseline urinary albumin-to-creatinine ratio (UACR) predicted cardiovascular outcomes, 2) changes in UACR differed between treatments, 3) benefits of losartan were related to its influence on UACR, and 4) reduction in albuminuria reduced cardiovascular events." | 9.12 | Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Ibsen, H; Lindholm, LH; Lyle, PA; Mogensen, CE; Olsen, MH; Snapinn, SM; Wachtell, K; Wan, Y, 2006) |
| "A total of 9193 hypertensive patients (1195 with diabetes) in the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study were treated with losartan- or atenolol-based regimens and followed up with serial ECG and blood pressure determinations at baseline and 6 months and then yearly until death or study end." | 9.12 | Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Edelman, JM; Gerdts, E; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Okin, PM; Snapinn, SM, 2006) |
| "In the LIFE study, with a double-masked, randomized, parallel-group design, 9193 patients (46% men) with hypertension (mean age 67 years, average pressure 174/98 mmHg after placebo run-in) and electrocardiogram-documented left ventricular hypertrophy were randomly assigned to once-daily losartan- or atenolol-based antihypertensive treatment and followed for at least 4 years (mean 4." | 9.10 | Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. ( Aurup, P; Beevers, G; Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Snapinn, S; Wachtell, K; Wedel, H, 2002) |
| "Treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy with losartan-based therapy is associated with lower incidence of diabetes mellitus and greater regression of hypertrophy than atenolol-based therapy." | 7.74 | In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) ( Dahlöf, B; Devereux, RB; Harris, KE; Jern, S; Kjeldsen, SE; Lindholm, LH; Okin, PM, 2007) |
| "To investigate the involvement of adrenergic mechanisms in the development of obesity, hyperglycaemia and hyperinsulinaemia in Aston ob/ob mice, the sympathomimetic agent ephedrine (12 mg/kg/day) and the predominantly beta 1-adrenergic antagonist atenolol (12 mg/kg/day) were administered alone and in combination to weanling ob/ob mice for 40 days." | 7.67 | Effects of ephedrine and atenolol on the development of obesity and diabetes in ob/ob mice. ( Bailey, CJ; Flatt, PR; Thornburn, CC, 1986) |
| "Losartan was very effective in reducing cardiovascular morbidity and mortality as compared to atenolol." | 6.71 | [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study]. ( Dahlöf, B; Ibsen, H; Kjeldsen, S; Lindholm, LH; Pedersen, OL, 2003) |
| "We assessed adverse metabolic effects of atenolol and hydrochlorothiazide among hypertensive patients with and without abdominal obesity using data from a randomized, open-label study of hypertensive patients without evidence of cardiovascular disease or diabetes mellitus." | 5.14 | Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. ( Beitelshees, AL; Boerwinkle, E; Chapman, AB; Cooper-DeHoff, RM; Gong, Y; Gums, JG; Hall, K; Johnson, JA; Parekh, V; Turner, ST; Wen, S; Zineh, I, 2010) |
| "Our current aims were to investigate whether 1) baseline urinary albumin-to-creatinine ratio (UACR) predicted cardiovascular outcomes, 2) changes in UACR differed between treatments, 3) benefits of losartan were related to its influence on UACR, and 4) reduction in albuminuria reduced cardiovascular events." | 5.12 | Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Ibsen, H; Lindholm, LH; Lyle, PA; Mogensen, CE; Olsen, MH; Snapinn, SM; Wachtell, K; Wan, Y, 2006) |
| "A total of 9193 hypertensive patients (1195 with diabetes) in the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study were treated with losartan- or atenolol-based regimens and followed up with serial ECG and blood pressure determinations at baseline and 6 months and then yearly until death or study end." | 5.12 | Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Edelman, JM; Gerdts, E; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Okin, PM; Snapinn, SM, 2006) |
| "In the LIFE study, with a double-masked, randomized, parallel-group design, 9193 patients (46% men) with hypertension (mean age 67 years, average pressure 174/98 mmHg after placebo run-in) and electrocardiogram-documented left ventricular hypertrophy were randomly assigned to once-daily losartan- or atenolol-based antihypertensive treatment and followed for at least 4 years (mean 4." | 5.10 | Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. ( Aurup, P; Beevers, G; Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Snapinn, S; Wachtell, K; Wedel, H, 2002) |
| "To compare efficacy and safety of atenolol, methoprolol and bisoprolol, as the most usable beta-blockers, in patients with isolated systolic arterial hypertension (ISAH) and concomitant diabetes mellitus (DM) and/or chronic obstructive pulmonary disease (COPD)." | 5.10 | [Efficacy and safety of different beta-blockers in patients with isolated systolic hypertension associated with diabetes mellitus and obstructive pulmonary diseases]. ( Abakumov, IuE; Batutina, AM; Kukes, VG; Mamaev, VI; Ostroumova, OD; Zykova, AA, 2003) |
| "Treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy with losartan-based therapy is associated with lower incidence of diabetes mellitus and greater regression of hypertrophy than atenolol-based therapy." | 3.74 | In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) ( Dahlöf, B; Devereux, RB; Harris, KE; Jern, S; Kjeldsen, SE; Lindholm, LH; Okin, PM, 2007) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a major reduction of all-cause mortality--especially cardiovascular mortality--in patients with diabetes with left ventricular hypertrophy was reported for treatment with losartan." | 3.72 | Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Edelman, JM; Ibsen, H; Lindholm, LH; Olsen, MH; Snapinn, S; Wachtell, K, 2003) |
| "To investigate the involvement of adrenergic mechanisms in the development of obesity, hyperglycaemia and hyperinsulinaemia in Aston ob/ob mice, the sympathomimetic agent ephedrine (12 mg/kg/day) and the predominantly beta 1-adrenergic antagonist atenolol (12 mg/kg/day) were administered alone and in combination to weanling ob/ob mice for 40 days." | 3.67 | Effects of ephedrine and atenolol on the development of obesity and diabetes in ob/ob mice. ( Bailey, CJ; Flatt, PR; Thornburn, CC, 1986) |
| "Losartan was very effective in reducing cardiovascular morbidity and mortality as compared to atenolol." | 2.71 | [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study]. ( Dahlöf, B; Ibsen, H; Kjeldsen, S; Lindholm, LH; Pedersen, OL, 2003) |
| "Atenolol or enalapril was the mandatory second-line drug." | 2.69 | Influence of diabetes and type of hypertension on response to antihypertensive treatment. ( Brown, MJ; Castaigne, A; de Leeuw, PW; Mancia, G; Palmer, CR; Rosenthal, T; Ruilope, LM, 2000) |
| "Atenolol treatment significantly increased triglyceride levels and decreased the HDL-cholesterol levels after 9 months in both groups." | 2.68 | Comparative effects of atenolol versus nifedipine on serum lipids and other biochemical parameters in diabetic and non-diabetic hypertensive subjects. ( Goyal, RK; Satia, MC; Shukla, ML, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (15.15) | 18.7374 |
| 1990's | 1 (3.03) | 18.2507 |
| 2000's | 20 (60.61) | 29.6817 |
| 2010's | 7 (21.21) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duan, L | 1 |
| Ng, A | 1 |
| Chen, W | 1 |
| Spencer, HT | 1 |
| Nguyen, J | 1 |
| Shen, AY | 1 |
| Lee, MS | 1 |
| Keating, E | 1 |
| Gonçalves, P | 1 |
| Campos, I | 1 |
| Costa, F | 1 |
| Martel, F | 1 |
| Manrique, C | 1 |
| Johnson, M | 1 |
| Sowers, JR | 1 |
| Cooper-DeHoff, RM | 2 |
| Wen, S | 1 |
| Beitelshees, AL | 2 |
| Zineh, I | 1 |
| Gums, JG | 2 |
| Turner, ST | 2 |
| Gong, Y | 2 |
| Hall, K | 1 |
| Parekh, V | 1 |
| Chapman, AB | 2 |
| Boerwinkle, E | 1 |
| Johnson, JA | 2 |
| Kaomongkolgit, R | 1 |
| Weber, MA | 1 |
| Karnes, JH | 1 |
| McDonough, CW | 1 |
| Vo, TT | 1 |
| Langaee, TY | 1 |
| Bailey, KR | 1 |
| Del-Aguila, JL | 1 |
| Boerwinkle, EA | 1 |
| Pepine, CJ | 3 |
| Monami, M | 1 |
| Filippi, L | 1 |
| Ungar, A | 1 |
| Sgrilli, F | 1 |
| Antenore, A | 1 |
| Dicembrini, I | 1 |
| Bagnoli, P | 1 |
| Marchionni, N | 1 |
| Rotella, CM | 1 |
| Mannucci, E | 1 |
| Lindholm, LH | 6 |
| Ibsen, H | 5 |
| Borch-Johnsen, K | 3 |
| Olsen, MH | 4 |
| Wachtell, K | 4 |
| Dahlöf, B | 7 |
| Devereux, RB | 4 |
| Beevers, G | 1 |
| de Faire, U | 1 |
| Fyhrquist, F | 2 |
| Julius, S | 2 |
| Kjeldsen, SE | 4 |
| Kristianson, K | 1 |
| Lederballe-Pedersen, O | 1 |
| Nieminen, MS | 1 |
| Omvik, P | 1 |
| Oparil, S | 1 |
| Wedel, H | 1 |
| Aurup, P | 1 |
| Edelman, JM | 3 |
| Snapinn, S | 2 |
| Malik, RA | 1 |
| Pedersen, OL | 1 |
| Kjeldsen, S | 1 |
| Aronow, WS | 1 |
| Sidorenko, BA | 1 |
| Ugriumova, MO | 1 |
| Kukes, VG | 1 |
| Ostroumova, OD | 1 |
| Mamaev, VI | 1 |
| Batutina, AM | 1 |
| Abakumov, IuE | 1 |
| Zykova, AA | 1 |
| Ong, HT | 1 |
| Chong, AY | 1 |
| Lip, GY | 1 |
| Bakris, GL | 2 |
| Gaxiola, E | 1 |
| Messerli, FH | 2 |
| Mancia, G | 2 |
| Erdine, S | 2 |
| Cooper-DeHoff, R | 2 |
| Franklin, SS | 1 |
| Papademetriou, V | 1 |
| Mogensen, CE | 1 |
| Snapinn, SM | 2 |
| Wan, Y | 1 |
| Lyle, PA | 1 |
| Okin, PM | 2 |
| Gerdts, E | 1 |
| Harris, KE | 2 |
| Jern, S | 2 |
| Baumgart, P | 1 |
| Cohen, JD | 1 |
| Hewkin, AC | 1 |
| Kupfer, S | 1 |
| Kølendorf, K | 1 |
| Jensen, HA | 1 |
| Holst, JJ | 1 |
| Poulsen, JE | 1 |
| Satia, MC | 1 |
| Shukla, ML | 1 |
| Goyal, RK | 1 |
| Brown, MJ | 1 |
| Castaigne, A | 1 |
| de Leeuw, PW | 1 |
| Palmer, CR | 1 |
| Rosenthal, T | 1 |
| Ruilope, LM | 1 |
| Levinson, PD | 1 |
| Bory, M | 1 |
| Lithell, H | 1 |
| Pollare, T | 1 |
| Berne, C | 1 |
| Opie, LH | 1 |
| Kwan, CM | 1 |
| Shepherd, AM | 1 |
| Johnson, J | 1 |
| Taylor, WF | 1 |
| Brockway, BA | 1 |
| Bailey, CJ | 1 |
| Thornburn, CC | 1 |
| Flatt, PR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Folic Acid Clinical Trial: Follow up of Children (FACT 4 Child)[NCT03269110] | 2,578 participants (Anticipated) | Observational | 2017-07-01 | Enrolling by invitation | |||
| Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)[NCT00246519] | Phase 4 | 1,701 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Prevention of Hypertension Incidence and Diabetes Italian Assessment Study. Therapeutic Strategies of Prevention of Diabetes and Hypertension in Subjects With Metabolic Syndrome and High-Normal Blood Pressure.[NCT00456963] | Phase 4 | 3,000 participants (Anticipated) | Interventional | 2007-09-30 | Terminated (stopped due to Because of delay in approval of the protocol by a number of Ethics Commitees the trial was terminated on March 4, 2010. No patient had received any study drug.) | ||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D)[NCT04545151] | Phase 2 | 138 participants (Anticipated) | Interventional | 2021-02-08 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00246519)
Timeframe: baseline to 18 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Atenolol +HCTZ Arm | -12.06 |
| HCTZ + Atenolol | -13.33 |
4 reviews available for atenolol and Diabetes Mellitus
| Article | Year |
|---|---|
Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Diabet | 2013 |
[New perspectives of the use of angiotensin II receptor blocker].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Diabetes Mellit | 2003 |
Beta-blockers, diabetes, and hypoglycemia: risky business?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2001 |
[Does diabetes change the anti-ischemic therapeutic options in the symptomatic coronary patient?].
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Antihypertensive Agents; Atenolol; Como | 2000 |
13 trials available for atenolol and Diabetes Mellitus
| Article | Year |
|---|---|
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Drug Therapy, Combina | 2010 |
Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment.
Topics: Aged; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Fasting; Female; Glucose; Haplotypes; Hu | 2013 |
Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Diabet | 2013 |
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Double-Blind Method; | 2002 |
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Double-Blind Method; | 2002 |
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Double-Blind Method; | 2002 |
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Double-Blind Method; | 2002 |
[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study].
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diabe | 2003 |
[Efficacy and safety of different beta-blockers in patients with isolated systolic hypertension associated with diabetes mellitus and obstructive pulmonary diseases].
Topics: Adrenergic beta-Antagonists; Atenolol; Bisoprolol; Blood Pressure; Blood Pressure Monitoring, Ambula | 2003 |
Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cr | 2006 |
Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Complications; Diabetes Mellitu | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Comparative effects of atenolol versus nifedipine on serum lipids and other biochemical parameters in diabetic and non-diabetic hypertensive subjects.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Blood Urea Nitrogen; Creatin | 1995 |
Influence of diabetes and type of hypertension on response to antihypertensive treatment.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers | 2000 |
Effects of long-term antihypertensive treatment on glucose metabolism.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Clinical Trials as Topic; Diabetes Mellitus; Dilt | 1989 |
Forearm and finger hemodynamics, blood pressure control, and lipid changes in diabetic hypertensive patients treated with atenolol and prazosin. A brief report.
Topics: Adult; Aged; Atenolol; Blood Pressure; Diabetes Complications; Diabetes Mellitus; Female; Fingers; F | 1989 |
17 other studies available for atenolol and Diabetes Mellitus
| Article | Year |
|---|---|
β-Blocker Exposure in Pregnancy and Risk of Fetal Cardiac Anomalies.
Topics: Adrenergic beta-Antagonists; Age Factors; Arrhythmias, Cardiac; Atenolol; Body Mass Index; Californi | 2017 |
Folic acid uptake by the human syncytiotrophoblast: interference by pharmacotherapy, drugs of abuse and pathological conditions.
Topics: Amphetamine; Antihypertensive Agents; Atenolol; Biological Transport; Cell Survival; Cells, Cultured | 2009 |
Thiazide diuretics alone or with beta-blockers impair glucose metabolism in hypertensive patients with abdominal obesity.
Topics: Adrenergic beta-Antagonists; Atenolol; Diabetes Mellitus; Diuretics; Drug Therapy, Combination; Fast | 2010 |
Oral lichenoid drug reaction associated with antihypertensive and hypoglycemic drugs.
Topics: Antihypertensive Agents; Atenolol; Chlorpropamide; Diabetes Complications; Diabetes Mellitus; Erythe | 2010 |
Hypertension: BP reduction in patients with diabetes--uncertainties remain.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers; Coronary Artery Disease | 2010 |
No morbidity-mortality. Commentary.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Atenolol; Diabe | 2002 |
Might losartan reduce sudden cardiac death in diabetic patients with hypertension?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Comorbidit | 2003 |
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Comorbidity; Dea | 2003 |
LIFE: losartan versus atenolol.
Topics: Antihypertensive Agents; Atenolol; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus; Drug Ther | 2003 |
LIFE: losartan versus atenolol.
Topics: Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Comorbidity; Death, Sudden, Cardiac; Diab | 2003 |
Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2004 |
Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy.
Topics: Adrenergic beta-Antagonists; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Animals; At | 2005 |
[Antihypertensive therapy: risk stratification in diabetes and cardiac diseases].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE)
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Comorbidity; Diabetes Me | 2007 |
Effect of acute selective beta-1-adrenoceptor blockade on hormonal and cardiovascular response to insulin-induced hypoglycaemia in insulin-dependent diabetic patients.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Atenolol; Blood Glucose; Diabetes Mellitus; Epinephr | 1982 |
Qualities of an ideal beta-adrenoceptor antagonist and comparison of existing agents with a new cardioselective hydrophilic vasodilator beta-adrenoceptor antagonist, celiprolol.
Topics: Adrenergic beta-Antagonists; Airway Resistance; Antihypertensive Agents; Atenolol; Celiprolol; Diabe | 1988 |
Effects of ephedrine and atenolol on the development of obesity and diabetes in ob/ob mice.
Topics: Aging; Animals; Atenolol; Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Experime | 1986 |